These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 6721448)

  • 21. Differences between anterior and posterior circulation stroke in TOAST.
    Libman RB; Kwiatkowski TG; Hansen MD; Clarke WR; Woolson RF; Adams HP
    Cerebrovasc Dis; 2001; 11(4):311-6. PubMed ID: 11385210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of a low molecular weight preparation of heparin--ORG 10172 (Lomoparan) in the critically ill.
    John G; Shehabi Y; Mudaliar Y
    Anaesth Intensive Care; 1991 Nov; 19(4):588-91. PubMed ID: 1721505
    [No Abstract]   [Full Text] [Related]  

  • 23. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis.
    Cade JF; Wood M; Magnani HN; Westlake GW
    Thromb Res; 1987 Mar; 45(5):497-503. PubMed ID: 3590088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172.
    Nieuwenhuis HK; Sixma JJ
    Cancer; 1986 Aug; 58(3):761-4. PubMed ID: 2425925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant.
    Frei U; Wilks MF; Boehmer S; Crisp-Lindgren N; Schwarzrock R; Stiekema JC; Koch KM
    Nephrol Dial Transplant; 1988; 3(4):435-9. PubMed ID: 2459635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
    Albanese MA; Clarke WR; Adams HP; Woolson RF
    Stroke; 1994 Sep; 25(9):1746-51. PubMed ID: 8073453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.
    Bradbrook ID; Magnani HN; Moelker HC; Morrison PJ; Robinson J; Rogers HJ; Spector RG; Van Dinther T; Wijnand H
    Br J Clin Pharmacol; 1987 Jun; 23(6):667-75. PubMed ID: 3606928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
    Gallus A; Murphy W; Nacey J; Morris M; Sutherland P; Marshall V; Magnani H
    Thromb Res; 1989 Oct; 56(2):229-38. PubMed ID: 2482549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
    De Boer A; Stiekema JC; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1991 Jul; 32(1):23-9. PubMed ID: 1716140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Moolenaar AJ; Breimer DD
    Eur J Clin Pharmacol; 1991; 41(3):245-50. PubMed ID: 1748141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Dabhoiwala NF
    Thromb Haemost; 1987 Feb; 57(1):92-6. PubMed ID: 2438799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans.
    Vogel GM; Meuleman DG; Bourgondiën FG; Hobbelen PM
    Thromb Res; 1989 Jun; 54(5):399-410. PubMed ID: 2549654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacology of polysaccharides of rheumatologial importance].
    Marmo E
    Clin Ter; 1979 Sep; 90(6):531-9. PubMed ID: 161218
    [No Abstract]   [Full Text] [Related]  

  • 34. Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.
    de Boer A; Stiekema JC; Danhof M; van Dinther TG; Boeijinga JK; Cohen AF; Breimer DD
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2110-5. PubMed ID: 1759835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One dimensional thin-layer cellulose chromatographic separation of dermatan-, heparan-, chondroitin- and keratan sulfate.
    Wang TR
    Taiwan Yi Xue Hui Za Zhi; 1984 Aug; 83(8):737-42. PubMed ID: 6240525
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
    Stiekema JC; Wijnand HP; Van Dinther TG; Moelker HC; Dawes J; Vinchenzo A; Toeberich H
    Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Potentiometry applied to the characterization and analysis of polysaccharides for pharmaceutical use].
    Mascellani G; Rasconi A; Brugnoli E; Bianchini P
    Farmaco Prat; 1988 May; 43(5):165-75. PubMed ID: 2972560
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clearing and anti-platelet-aggregation effects of a heparinoid of natural origin].
    Marini U; Bastoni F; Gibelli A
    Clin Ter; 1974 Oct; 71(1):13-31. PubMed ID: 4138995
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Breimer DD
    J Clin Pharmacol; 1991 Jul; 31(7):611-7. PubMed ID: 1716644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new technique in the treatment of thromboembolic stroke Preliminary Report.
    Leon-Sotomayor L
    Angiology; 1980 Nov; 31(11):729-43. PubMed ID: 6161569
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.